Get startedLog in
    Picture of Phaxiam Therapeutics SA logo

    PHXM — Phaxiam Therapeutics SA News Story

    0.000.00%
    fr flag iconLast trade - 00:00
    HealthcareHighly SpeculativeMicro CapValue Trap
    All News

    Brief: Erytech Announces Maximum Tolerated Dose Declared In A Phase 1 Investigator Sponsored Trial Oferyaspase In First-Line Pancreatic Cancer

    Picture of Phaxiam Therapeutics SA logoPhaxiam Therapeutics SA
    04/10/2021 21:12
    Oct 4 (Reuters) - Erytech Pharma SA  ERYP.PA :
    * ERYTECH ANNOUNCES MAXIMUM TOLERATED DOSE DECLARED IN A
PHASE 1
INVESTIGATOR SPONSORED TRIAL OFERYASPASE IN FIRST-LINE
PANCREATIC CANCER

Source text for Eikon:  ID:nGNXnNpJH 
Further company coverage:  ERYP.PA 

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Phaxiam Therapeutics SA

    See all news